280 related articles for article (PubMed ID: 32703310)
1. A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data.
Morin KA; Eibl JK; Gauthier G; Rush B; Mushquash C; Lightfoot NE; Marsh DC
Harm Reduct J; 2020 Jul; 17(1):51. PubMed ID: 32703310
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the effectiveness of concurrent opioid agonist treatment and physician-based mental health services for patients with mental disorders in Ontario, Canada.
Morin KA; Eibl JK; Caswell JM; Rush B; Mushquash C; Lightfoot NE; Marsh DC
PLoS One; 2020; 15(12):e0243317. PubMed ID: 33338065
[TBL] [Abstract][Full Text] [Related]
3. A Retrospective Cohort Study Comparing In-Person and Telemedicine-Based Opioid Agonist Treatment in Ontario, Canada, Using Administrative Health Data.
Morin KA; Parrotta MD; Eibl JK; Marsh DC
Eur Addict Res; 2021; 27(4):268-276. PubMed ID: 33706309
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study.
Paul LA; Bayoumi AM; Chen C; Kocovska E; Smith BT; Raboud JM; Gomes T; Kendall C; Rosella LC; Bitonti-Bengert L; Rush B; Yu M; Spithoff S; Crichlow F; Wright A; Watford J; Besharah J; Munro C; Taha S; Nosyk B; Strike C; Manson H; Kahan M; Leece P
Addiction; 2023 Apr; 118(4):686-697. PubMed ID: 36401610
[TBL] [Abstract][Full Text] [Related]
5. Concurrent psychiatry for patients enrolled in opioid agonist treatment: a propensity score matched cohort study in Ontario Canada.
Morin KA; Eibl JK; Caswell JM; Gauthier G; Rush B; Mushquash C; Lightfoot NE; Marsh DC
Subst Abuse Treat Prev Policy; 2019 Jun; 14(1):29. PubMed ID: 31242949
[TBL] [Abstract][Full Text] [Related]
6. Inequities in access to primary care among opioid recipients in Ontario, Canada: A population-based cohort study.
Gomes T; Campbell TJ; Martins D; Paterson JM; Robertson L; Juurlink DN; Mamdani M; Glazier RH
PLoS Med; 2021 Jun; 18(6):e1003631. PubMed ID: 34061846
[TBL] [Abstract][Full Text] [Related]
7. A retrospective cohort study evaluating correlates of deep tissue infections among patients enrolled in opioid agonist treatment using administrative data in Ontario, Canada.
Morin KA; Prevost CR; Eibl JK; Franklyn MT; Moise AR; Marsh DC
PLoS One; 2020; 15(4):e0232191. PubMed ID: 32330184
[TBL] [Abstract][Full Text] [Related]
8. Exploring dual diagnosis in opioid agonist treatment patients: a registry-linkage study in Czechia and Norway.
Rolová G; Skurtveit S; Gabrhelík R; Mravčík V; Odsbu I
Addict Sci Clin Pract; 2024 May; 19(1):37. PubMed ID: 38741162
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting.
Eibl JK; Gauthier G; Pellegrini D; Daiter J; Varenbut M; Hogenbirk JC; Marsh DC
Drug Alcohol Depend; 2017 Jul; 176():133-138. PubMed ID: 28535455
[TBL] [Abstract][Full Text] [Related]
10. Opioid agonist therapy during residential treatment of opioid use disorder: Cohort study on access and outcomes.
Spithoff S; Meaney C; Urbanoski K; Harrington K; Que B; Kahan M; Leece P; Shehadeh V; Sullivan F
Can Fam Physician; 2019 Oct; 65(10):e443-e452. PubMed ID: 31604755
[TBL] [Abstract][Full Text] [Related]
11. The impact of cocaine use in patients enrolled in opioid agonist therapy in Ontario, Canada.
Franklyn AM; Eibl JK; Gauthier GJ; Pellegrini D; Lightfoot NE; Marsh DC
Int J Drug Policy; 2017 Oct; 48():1-8. PubMed ID: 28666202
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the association between urine drug screening frequency and retention in opioid agonist treatment in Ontario, Canada: a retrospective cohort study.
Morin KA; Dabous JR; Vojtesek F; Marsh D
BMJ Open; 2022 Oct; 12(10):e060857. PubMed ID: 36223960
[TBL] [Abstract][Full Text] [Related]
13. The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada.
Piske M; Zhou H; Min JE; Hongdilokkul N; Pearce LA; Homayra F; Socias ME; McGowan G; Nosyk B
Addiction; 2020 Aug; 115(8):1482-1493. PubMed ID: 31899565
[TBL] [Abstract][Full Text] [Related]
14. Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study.
Pearce LA; Min JE; Piske M; Zhou H; Homayra F; Slaunwhite A; Irvine M; McGowan G; Nosyk B
BMJ; 2020 Mar; 368():m772. PubMed ID: 32234712
[TBL] [Abstract][Full Text] [Related]
15. Postoperative buprenorphine continuation in stabilized buprenorphine patients: A population cohort study.
Hauck TS; Ladha KS; Le Foll B; Wijeysundera DN; Kurdyak P
Addiction; 2023 Oct; 118(10):1953-1964. PubMed ID: 37332171
[TBL] [Abstract][Full Text] [Related]
16. Canadian Addiction Treatment Centre (CATC) opioid agonist treatment cohort in Ontario, Canada.
Morin KA; Tatangelo M; Marsh D
BMJ Open; 2024 Feb; 14(2):e080790. PubMed ID: 38401902
[TBL] [Abstract][Full Text] [Related]
17. Initiation of opioid agonist therapy after hospital visits for opioid poisonings in Ontario.
Hu T; McCormack D; Juurlink DN; Campbell TJ; Bayoumi AM; Leece P; Kent JT; Gomes T
CMAJ; 2023 Dec; 195(49):E1709-E1717. PubMed ID: 38110219
[TBL] [Abstract][Full Text] [Related]
18. Measuring treatment attrition at various stages of engagement in Opioid Agonist Treatment in Ontario Canada using a cascade of care framework.
Tahsin F; Morin KA; Vojtesek F; Marsh DC
BMC Health Serv Res; 2022 Apr; 22(1):490. PubMed ID: 35413980
[TBL] [Abstract][Full Text] [Related]
19. Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions.
Bouck Z; Scheim AI; Gomes T; Ling V; Caudarella A; Werb D
Int J Drug Policy; 2022 Jun; 104():103680. PubMed ID: 35447476
[TBL] [Abstract][Full Text] [Related]
20. Exploring mental health comorbidities and opioid agonist treatment coverage among people in prison: A national cohort study 2010-2019.
Bukten A; Skjærvø I; Stavseth MR
Drug Alcohol Depend; 2023 Sep; 250():110896. PubMed ID: 37515826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
